Literature DB >> 17639057

HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.

Raffaele Ciampi1, Thomas J Giordano, Kathryn Wikenheiser-Brokamp, Ronald J Koenig, Yuri E Nikiforov.   

Abstract

Chromosomal rearrangements of the RET proto-oncogene (RET/PTC) are the common feature of papillary thyroid carcinoma (PTC). In this study, we report the identification, cloning, and functional characterization of a novel type of RET/PTC rearrangement that results from the fusion of the 3'-portion of RET coding for the tyrosine kinase (TK) domain of the receptor to the 5'-portion of the Homo sapiens hook homolog 3 (HOOK3) gene. The novel fusion was identified in a case of PTC that revealed a gene expression signature characteristic of RET/PTC on DNA microarray analysis, but was negative for the most common types of RET rearrangement. A fusion product between exon 11 of HOOK3 and exon 12 of RET gene was identified by 5'RACE, and the presence of chimeric HOOK3-RET protein of 88 kDa was detected by western blot analysis with an anti-RET antibody. The protein is predicted to contain a portion of the coiled-coil domains of HOOK3 and the intact TK domain of RET. Expression of the HOOK3-RET cDNA in NIH3T3 cells resulted in the formation of transformed foci and in tumor formation after injection into nude mice, confirming the oncogenic nature of HOOK3-RET.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639057     DOI: 10.1677/ERC-07-0039

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

1.  Papillary thyroid carcinoma in a 5-year-old child-case report.

Authors:  B N Gayathri; A Sagayaraj; S Prabhakara; T N Suresh; Merchant Shuaib; S M Azeem Mohiyuddin
Journal:  Indian J Surg Oncol       Date:  2014-03-11

Review 2.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

Review 3.  Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.

Authors:  Mian Liu; Pei Chen; Hui-Yu Hu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Hai-Long Tan; Peng Huang; Shi Chang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 4.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

Review 5.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

6.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

Review 7.  Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma.

Authors:  Manoj Gandhi; Viktoria Evdokimova; Yuri E Nikiforov
Journal:  Mol Cell Endocrinol       Date:  2009-09-18       Impact factor: 4.102

8.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 9.  Tyrosine kinase gene rearrangements in epithelial malignancies.

Authors:  Alice T Shaw; Peggy P Hsu; Mark M Awad; Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.